A genomic test called Decipher could help personalize prostate cancer treatment by identifying which men benefit from abiraterone hormone therapy, UCL research suggests.
A genomic test called Decipher could help personalize prostate cancer treatment by identifying which men benefit from abiraterone hormone therapy, UCL research suggests.
